anti obesity drugs Flashcards

1
Q

what constitutes to being obese

A

bmi over 30

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what diseases does obesity contribute to

A

coranary heart disease, type 2 diabetes, osteoarthritis, certain forms of cancer, impotence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

how is meal number and size regulated

A

end of feeding is promoted by satiety factors that increase during feeding

these generate signals in brain through peripheral nerves innervating the nucleus of the solitary tract as well as directly activating their own receptors

information is then transmitted to hypothalamus and forebrain areas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what receptors are involved in regulation of meals

A

peripheral receptors in gut (distension and chemo-receptors) and metabolic changes send signals to brain via vagus nerve

receptors in CNS which detect circulating levels of nutrients

neuroactive factors which cross blood-brain barrier and/or are released in the brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

how is control of food take regulated centrally

A

via hypothalamic nuclei which:

maintains homeostasis

is site of release of numerous neurotransmitters (monoamines and peptides) that influence food intake

have strong links with central and autonomic nervous systems as well as endocrine system

several hypothalamic nuclei are involved in regulation of food intake, each nucleus contains peptidergic neurones with opposing effects on food intake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

how does brain modification affect feeding

A

lesions of ventromedial hypothalamus causes obesity and overeating

lesions of laterhypothalamus causes reduction in food intake and bodyweight

injection of glucose antimetabolites into 4th ventricle induces feeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are key hypothalamic nuclei

A

arcuate nucleus: different sets of neurones;
one set in which neuropeptide Y and AgRP are colocalised

or set which uses POMC

both groups in arcuate nucleus are sensitive to leptin

these neurones have reciprocal connections with the paraventricular nucleus, dorsomedial nucleus and lateral hypothalamic area

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

how do brainstem nuclei regulate feeding

A

these are source of neurones that regulate hypothalamic function

neurones integrate and resond to afferent signals from digestive tract

neurones here are targets for leptin, especially the nucleus of the solitary tract which is innervated by vagal afferents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

how are other central areas involved in feeding

A

amygdala involved in food intake; has emotional influence on hunger/satiety

nucleus accumbent: food intake associated with reward pathway, dopamine receptors effect motor activity and duration of feeding but not total food intake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are central orexogenic factors, give examples

A

factors that increase food intake:

neuropeptide Y, AgRP(agouti related peptide), endocannabinoids

opioids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how does neuropeptide Y increase food intake

A

released from neurones w cell bodies in arcuate nucleus which project to paraventricular nucleus

these neurones are activated by declines in fat stores and ihibited by feedback caused by insulin and leptin

stimulation of these neurones reduces sympathetic outflow to brown adipose tissue and so lowers energy expenditure and stimulates lipogenesis

production of neuropeptide Y may be inhibited by leptin and desensitisation of NPYergic neurones may impair satiety and so regulation of meal size which may contribute to obesity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

how does AgRP cause its effects

A

orexegenic

colocalised w NPY

is an antagonist of melanocortin system

disruption of AgRP synthesis reduces body weight and increases metabolism but does not effect food intake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

how do endocannabinoids cause their effects

A

orexegenic

peripheral administration of anandamide increases food intake

expalins munchies associated with cannabis use

CB1 antagonists reduce food intake

fasting leads to accumulation of anandamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are central anorexegenic factors, give examples

A
factors that reduce food intake:
melanocortins
5HT
noradrenaline
dopamine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

how do melanocortins produce their effect

A

anorexogenic

they are derived from POMC (pre-opiomelanocortin)

potently reduce food intake and increase energy expenditure through activation of MC3 and MC4 receptors

e.g alpha-melanocyte stimulating hormone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

how does 5HT affect food intake

A

anorexegenic

effects attributed to activation of 5HT2c receptors

actions mediated in paraventricular nucleus, possibly by inhibiting NPY

may suppress preference for fat intake

intake of carbohydrate can increase 5HT release in brain,via release of insulin which promotes uptake of tryptophan (5HT precursor) which may augment effects on satiety (controversial)

17
Q

how does NA affect food intake

A

anorexogenic

noradrenaline: reduce food intake thought to rely on stimulation of alpha1 and beta receptors in hypothalamus

18
Q

what are key peripheral mediators of food intake

A

leptin, insulin, gherkin, peptide YY, cholecystokinin, glucocorticoids, GLP-1

19
Q

how does leptin effect feeding

A

anorexogenic

stimulates POMC, inhibits NPY in hypothalamus

stimulates GLP-1 in brainstem

thought to act on satiety centre of hypothalamus to reduce fat deposition and hence body weight by decreasing food intake and increasing energy expenditure

increase in fat stores increases leptin production, decline reduces production

mice lacking genes for leptin or its receptors are obese

20
Q

how does ghrelin effect feeding

A

orexogenic:

secreted by stomach, regulated by leptin, secretion increase during fasting and falls after eating

inhibits 5HT release

21
Q

how does insulin effect feeding

A

actions resemble leptin, stimulates release of leptin

enters brain through specific transporters, reduces NPY synthesis, stimulates POMC synthesis

under some circumstances insulin can also increase food intake

22
Q

how do peptide YY, cholecystokinin, GLP-1 and glucocorticoids effect feeding

A

peptide YY: inhibits feeding, produced by gut

cholecystokinin: inhibits feeding, increases release of 5HT in thalamus, meal termination signal
glucocorticoids: orexogenic, are leptin/insulin antagonists

GLP-1: anorexogenic, incretin causes glucose lowering effect, GLP-1 analogues are anti-diabetic drugs, also caused sustained weight loss

23
Q

what drugs are used to treat obesity

A

sibutramine, orlistat, lorcaserin, GLP-1 analogues

24
Q

how does sibutramine cause weight loss

A

5HT/ noradrenaline reuptake inhibitor

is a prodrug, undergoes extensive first pass metabolism; 2 active metabolites which inhibit reuptake of 5HT and NA

promotes activation of beta 2 receptors in adipose tissue

adverse effects are due to increased sympathetic drive: increase in blood pressure

25
Q

how does orlistat cause weight loss

A

inhibits pancreatic lipase; prevents breakdown of fat to fatty acids and glycerols

increases faecal fat and so patients must adhere to low fat diet to avoid unpleasant effects

only anti-obesity drug not to be withdrawn from market (d-flenfluramine and related drugs withdrawn)

low patient compliance due to unpleasant gastric effects

26
Q

how does lorcaserin cause fat loss

A

5HT2c receptor antagonist

increases melanocortin production from POMC neurones

27
Q

how are GLP-1 analgoues used to treat obesity

A

e.g liraglutide and exenatide

cross blood brain barrier, act on GLP-1 receptors

act on various regions such as hypothalamus and mesolimbic system to supress both reward driven and metabolically motivated food intake

they are peptide; have to be injected so are less attractive to patient and are relatively expensive

28
Q

how is gastric bypass surgery used in treatment of obesity

A

most efficient weight loss treatment, however serious surgical risks and high cost

changes in GLP-1 system may underlie some of its beneficial effects

29
Q

what are types of gastric bypass surgery

A

roux-en-Y gastric bypass: alimentary limb in connected to mid jejunum, leads to reduction in functional volume of stomach by over 90%

sleeve gastrectomy: does not alter route for nutrients, reduces stomack to about 15% of its original size by removal of large proportion of stomach along greater curvature

30
Q

how does gastric bypass surgery effect GLP-1

A

fasting GLP-1 levels not altered

enhanced postprandial GLP-1 responses observed 1-3 days after surgery

GLP-1 response greater after roux-en-Y bypass than sleeve gastrectomy

enhanced GLP-1 response was not observed in patients who were calorie restricted

progressive increase in GLP-1 response during first year after surgery, persists long term, changes are much more than incretin counterpart which is not altered

31
Q

what are consequences of gastric bypass surgery

A

CV: decrease in CV disease and hypercholesterolaemia
decrease in hypertension and inflammation

decrease in obstructive sleep apnoea

central: decreased appetite and increased satiety, increased cognitive function

GIT: altered bile acids, increased PYY, altered gut microbiota

increase GLP-1, decreased gherkin, increased insulin

32
Q

what is summary of treatment

A

sustained life style changes such as balanced diet and exercise may be healthiest way to loose weight

surgery is most effective, however targeting circulating factors is easier, less risky and expensive

NT receptor targets are difficult to target due to side effects